Bortezomib in Patients With Chronic Graft Versus Host Disease

Bone marrow transplantation offers great promise for the treatment of a variety of diseases,
particularly hematological malignancies. The incidence of acute GVHD has significantly
decreased due to significant improvements in human leukocyte antigen (HLA) matching of the
donors and recipients, more efficient GVHD prophylaxis regimens and the use of
reduced-intensity preparative regimen. However, cGVHD remains a significant cause for
increased morbidity and mortality associated with allogeneic stem cell transplantation.

While many of the patients with cGVHD respond initially to higher doses of steroids, cGVHD
usually relapses during or following steroid taper. Because of the significant impact of
steroids on this patient population, there is an urgent need for medications to take the
place of high dose steroid use in this patient population.

We hypothesize that bortezomib can modulate the immune system and can be used to treat GVHD.
At the same time bortezomib post transplant can induce a graft versus leukemia or lymphoma
effect. Bortezomib has been used with minimal toxicity in post transplant setting for
patients with aggressive multiple myeloma and also for acute graft versus host disease.

Inclusion Criteria:

- Voluntary written informed consent

- Female subject is either postmenopausal for at least 1 year before the screening
visit, is surgically sterilized or if they are of childbearing potential, agree to
practice 2 effective methods of contraception from the time of signing the informed
consent form through 30 days after the last dose of bortezomib, or agree to completely
abstain from heterosexual intercourse.

- Male subjects, even if surgically sterilized must agree to 2 effective methods of
contraception.

- Patients with chronic GVHD that involves 3 or more organs or with a score of 2 or
greater in any single organ based on NIH cGVHD grading

- Any previous treatments for cGVHD (except study drug). Participants may have received
study drug for other reasons besides cGVHD such as leukemia or solid tumor.

- Except for steroid refractory or intolerant cases, participants must be receiving
baseline systemic glucocorticoid therapy for cGVHD at study entry. The dose of
steroids must be stable for 14 days prior to starting study drug.

- At the time of trial enrollment, participants may be receiving one or two other
immunosuppressive therapies in addition to glucocorticoids.

- Chronic GVHD manifestations that can be followed on physical or laboratory exam.

- Age >18 years old

- ECOG performance status < 2. Patients with ECOG performance status of 3 (defined as
being capable of only limited self-care, confined to bed or chair more than 50% of
waking hours) will also be eligible only if the lower performance status is judged to
be directly related to steroid and/or cGVHD effects.

- Myeloablative or non-myeloablative allogeneic hematopoietic cell transplant.

Exclusion Criteria:

- Patients with irreversible damage as the only manifestation of chronic GVHD
(irreversible contractures or sicca syndrome)

- Active uncontrolled infection

- Contraindications to administration of bortezomib

- Relapsed disease or development of other malignancies

- Laboratory parameters:

ANC <1 x 10^9/L Platelets < 50 x 10^9/L Bilirubin >1.5 upper limit of normal (ULN) when it
is clearly not related to GVHD. EF <45% DLCO <45% Creatinine clearance <30 Aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN

- Platelet count of <50 within 5 days before enrollment.

- Absolute neutrophil count of <1000 within 5 days before enrollment.

- Patient has > Grade 2 peripheral neuropathy

- Patient had myocardial infarction within 6 months prior to enrollment or has New York
Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities. Prior to study entry, any ECG
abnormality at screening must be documented by the investigator as not medically
relevant.

- Patient has hypersensitivity to bortezomib, boron, or mannitol.

- Female subject is pregnant or lactating.

- Female patients who are lactating or have a positive serum pregnancy test during the
screening period, or a positive urine pregnancy test on Day 1 before first dose of
study drug, if applicable.

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

- Diagnosed or treated for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

- Participation in clinical trials with other investigational agents not included in
this trial, within 14 days of the start of this trial and throughout the duration of
this trial.

- Radiation therapy within 3 weeks before randomization. Enrollment of subjects who
require concurrent radiotherapy (which must be localized in its field size) should be
deferred until the radiotherapy is completed and 3 weeks have elapsed since the last
date of therapy.